{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:18:31Z","timestamp":1795133911627,"version":"4.10.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Using data collected in the prospective observational study CIRSE Registry for SIR-Spheres Therapy, the present study aimed at identifying predictors of adverse events (AEs) following transarterial radioembolization (TARE) with Yttrium-90 resin microspheres for liver tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 1027 patients enrolled between January 2015 and December 2017 and followed up for 24\u00a0months. Four hundred and twenty-two patients with hepatocellular carcinoma (HCC), 120 with intrahepatic carcinoma (ICC), 237 with colorectal liver metastases and 248 with liver metastases from other primaries were included. Prognostic factors were calculated with a univariable analysis by using the overall AEs burden score (AEBS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All-cause AEs were reported in 401\/1027 (39.1%) patients, with AEs associated with TARE, such as abdominal pain (16.6%), fatigue (17%), and nausea (11.7%) reported most frequently. Grade 3 or higher AEs were reported in 92\/1027 (9%) patients. Reports on grade\u2009\u2265\u20093 gastrointestinal ulcerations (0.4%), gastritis (0.3%), radiation cholecystitis (0.2%) or radioembolization-induced liver disease (0.5%) were uncommon. Univariable analysis showed that in HCC, AEBS increased for Eastern Cooperative Oncology Group (ECOG) 0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0045), 1 tumour nodule (0.0081),\u2009 &gt;\u20091 TARE treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0224), no\u00a0prophylactic embolization (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0211),\u00a0partition model dosimetry (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0007) and unilobar treatment target (0.0032). For ICC,\u2009 &gt;\u20091 TARE treatment was associated with an increase in AEBS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0224), and for colorectal liver metastases, ECOG 0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0188),\u2009&gt;\u20092 prior systemic treatments (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0127), and 1 tumour nodule (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0155) were associated with an increased AEBS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study confirms that TARE is a safe treatment with low toxicity and a minimal impact on quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-023-03391-4","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T18:02:38Z","timestamp":1678730558000},"page":"852-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study"],"prefix":"10.1007","volume":"46","author":[{"given":"Geert","family":"Maleux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bargellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helmberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kolligs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Munneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Peynircioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bleranda","family":"Zeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-2973","authenticated-orcid":false,"given":"Niels","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I.","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CIRT Principal Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"D\u2019Archambeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugsan","family":"Balli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadik","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Golfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Robert","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Kuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"\u00d6zg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Maleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helmberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pfammatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"5","key":"3391_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541\u201365.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"3391_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 22021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329\u201359.","journal-title":"J Natl Compr Canc Netw."},{"key":"3391_CR3","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","DOI":"10.1016\/j.jhep.2011.12.001"},{"issue":"1","key":"3391_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address EEE, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol."},{"issue":"7","key":"3391_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00259-011-1812-2","volume":"38","author":"F Giammarile","year":"2011","unstructured":"Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393\u2013406.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 5","key":"3391_CR6","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28\u201337.","journal-title":"Ann Oncol"},{"issue":"8","key":"3391_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"issue":"5","key":"3391_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/annonc\/mdy510","volume":"30","author":"A Vogel","year":"2019","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871\u20133.","journal-title":"Ann Oncol"},{"issue":"2","key":"3391_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"1","key":"3391_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00270-020-02643-x","volume":"44","author":"R Loffroy","year":"2021","unstructured":"Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, et al. Short-term Safety and quality of life outcomes following radioembolization in primary and secondary liver tumours: a multi-centre analysis of 200 patients in France. Cardiovasc Intervent Radiol. 2021;44(1):36\u201349.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"3391_CR11","doi-asserted-by":"publisher","first-page":"e0184597","DOI":"10.1371\/journal.pone.0184597","volume":"12","author":"K Katsanos","year":"2017","unstructured":"Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS ONE. 2017;12(9):e0184597.","journal-title":"PLoS ONE"},{"issue":"5","key":"3391_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3391_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.220387","volume":"305","author":"EC Emmons","year":"2022","unstructured":"Emmons EC, Bishay S, Du L, Krebs H, Gandhi RT, Collins ZS, et al. Survival and toxicities after (90)Y transarterial radioembolization of metastatic colorectal cancer in the RESIN registry. Radiology. 2022;305(1):228\u201336.","journal-title":"Radiology"},{"issue":"6","key":"3391_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jvir.2021.03.535","volume":"32","author":"S Frantz","year":"2021","unstructured":"Frantz S, Matsuoka L, Vaheesan K, Petroziello M, Golzarian J, Wang E, et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization: analysis of the RESiN registry. J Vasc Interv Radiol. 2021;32(6):845\u201352.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"3391_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159\u201371.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3391_CR16","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/cancers12113251","volume":"12","author":"JG Le-Rademacher","year":"2020","unstructured":"Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, et al. Adverse event burden score-A versatile summary measure for cancer clinical trials. Cancers. 2020;12(11):3251.","journal-title":"Cancers"},{"issue":"4","key":"3391_CR17","doi-asserted-by":"publisher","first-page":"e16296","DOI":"10.2196\/16296","volume":"9","author":"T Helmberger","year":"2020","unstructured":"Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, et al. Clinical application of radioembolization in hepatic malignancies: protocol for a prospective multicenter observational study. JMIR Res Protoc. 2020;9(4):e16296.","journal-title":"JMIR Res Protoc"},{"issue":"3","key":"3391_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00270-009-9717-1","volume":"33","author":"JI Bilbao","year":"2010","unstructured":"Bilbao JI, Garrastachu P, Herraiz MJ, Rodriguez M, Inarrairaegui M, Rodriguez J, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Intervent Radiol. 2010;33(3):523\u201331.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"Suppl 2","key":"3391_CR19","doi-asserted-by":"publisher","first-page":"104s","DOI":"10.2967\/jnumed.116.187229","volume":"58","author":"FE Boas","year":"2017","unstructured":"Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med. 2017;58(Suppl 2):104s-s111.","journal-title":"J Nucl Med"},{"issue":"5","key":"3391_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4329\/wjr.v8.i5.449","volume":"8","author":"AH Mahnken","year":"2016","unstructured":"Mahnken AH. Current status of transarterial radioembolization. World J Radiol. 2016;8(5):449\u201359.","journal-title":"World J Radiol"},{"key":"3391_CR21","unstructured":"Fayers PM AN, Bjordal K, Groenvold M, Curran D, Bottomley A, on, Group. botEQoL. The EORTC QLQ-C30 Scoring Manual, 3rd edition. European Organisation for Research and Treatment of Cancer. 2001."},{"issue":"1","key":"3391_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","volume":"44","author":"T Helmberger","year":"2021","unstructured":"Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"3391_CR23","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","volume":"5","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, et al. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study. JHEP Rep. 2023;5(2):100633.","journal-title":"JHEP Rep"},{"key":"3391_CR24","doi-asserted-by":"crossref","unstructured":"Schaefer N, Grozinger G, Pech M, Pfammatter T, Soydal C, Arnold D, et al. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022.","DOI":"10.1016\/j.clcc.2022.09.002"},{"issue":"2","key":"3391_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","volume":"29","author":"MN Braat","year":"2017","unstructured":"Braat MN, van Erpecum KJ, Zonnenberg BA, van den Bosch MA, Lam MG. Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol. 2017;29(2):144\u201352.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"3391_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/COC.0b013e318168ef65","volume":"31","author":"R Salem","year":"2008","unstructured":"Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"13","key":"3391_CR27","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","volume":"47","author":"C Chiesa","year":"2020","unstructured":"Chiesa C, Mira M, Bhoori S, Bormolini G, Maccauro M, Spreafico C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3391_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/RLU.0000000000002828","volume":"45","author":"M Elsayed","year":"2020","unstructured":"Elsayed M, Ermentrout RM, Sethi I, Bercu ZL, Galt JR, Whitmore M, et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med. 2020;45(2):100\u20134.","journal-title":"Clin Nucl Med"},{"issue":"10","key":"3391_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12032-017-1021-3","volume":"34","author":"C Floridi","year":"2017","unstructured":"Floridi C, Pesapane F, Angileri SA, De Palma D, Fontana F, Caspani F, et al. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol. 2017;34(10):174.","journal-title":"Med Oncol"},{"issue":"2","key":"3391_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.21037\/jgo-20-346","volume":"12","author":"D Brown","year":"2021","unstructured":"Brown D, Krebs H, Brower J, O\u2019Hara R, Wang E, Vaheesan K, et al. Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry. J Gastrointest Oncol. 2021;12(2):639\u201357.","journal-title":"J Gastrointest Oncol"},{"issue":"19","key":"3391_CR31","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3391_CR32","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3391_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00270-017-1594-4","volume":"40","author":"JR Kallini","year":"2017","unstructured":"Kallini JR, Gabr A, Thorlund K, Balijepalli C, Ayres D, Kanters S, et al. Comparison of the adverse event profile of therasphere((R)) with SIR-spheres((R)) for the treatment of unresectable hepatocellular carcinoma: a systematic review. Cardiovasc Intervent Radiol. 2017;40(7):1033\u201343.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"3391_CR34","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","volume":"30","author":"BM Currie","year":"2019","unstructured":"Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol. 2019;30(12):1915\u201323.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3391_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28(1):1\u201315.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3391_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3391_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2967\/jnumed.120.243832","volume":"62","author":"C van Roekel","year":"2021","unstructured":"van Roekel C, Bastiaannet R, Smits MLJ, Bruijnen RC, Braat A, de Jong H, et al. Dose-effect relationships of (166)Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272\u20139.","journal-title":"J Nucl Med"},{"issue":"11","key":"3391_CR38","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","volume":"62","author":"AA Alsultan","year":"2021","unstructured":"Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for glass (90)Y radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med. 2021;62(11):1616\u201323.","journal-title":"J Nucl Med"},{"issue":"4_suppl","key":"3391_CR39","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1200\/JCO.2020.38.4_suppl.516","volume":"38","author":"E Garin","year":"2020","unstructured":"Garin E, Tzelikas L, Guiu B, Chalaye J, Edeline J, De Baere T, Tacher V, Robert C, Assenat E, Terroir-Cassou-Mounat M, Regnault H, Palard X, Laffont S, Campillo-Gimenez B, Rolland Y. Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01). J Clin Oncol. 2020;38(4_suppl):516\u2013516. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.516.","journal-title":"J Clin Oncol"},{"key":"3391_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12875-016-0408-0","volume":"17","author":"S Lang","year":"2016","unstructured":"Lang S, Velasco Garrido M, Heintze C. Patients\u2019 views of adverse events in primary and ambulatory care: a systematic review to assess methods and the content of what patients consider to be adverse events. BMC Fam Pract. 2016;17:6.","journal-title":"BMC Fam Pract"},{"issue":"5","key":"3391_CR41","first-page":"e33","volume":"19","author":"JJ Mira","year":"2010","unstructured":"Mira JJ, Nebot C, Lorenzo S, Perez-Jover V. Patient report on information given, consultation time and safety in primary care. Qual Saf Health Care. 2010;19(5):e33.","journal-title":"Qual Saf Health Care"},{"issue":"2","key":"3391_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jvir.2019.06.018","volume":"31","author":"R Salem","year":"2020","unstructured":"Salem R, Hassan S, Lewandowski RJ, Grace K, Martin RCG, Sichlau MJ, et al. Quality of life after radioembolization for hepatocellular carcinoma using a digital patient-reported outcome tool. J Vasc Interv Radiol. 2020;31(2):311\u20134.","journal-title":"J Vasc Interv Radiol."},{"issue":"1","key":"3391_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12885-017-3921-1","volume":"18","author":"M Xing","year":"2018","unstructured":"Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer. 2018;18(1):75.","journal-title":"BMC Cancer"},{"issue":"12","key":"3391_CR44","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.jvir.2019.07.020","volume":"30","author":"A Das","year":"2019","unstructured":"Das A, Gabr A, O\u2019Brian DP, Riaz A, Desai K, Thornburg B, Kallini JR, Mouli S, Lewandowski RJ, Salem R. Contemporary systematic review of health-related quality of life outcomes in locoregional therapies for hepatocellular carcinoma. J Vascul Int Radiol. 2019;30(12):1924-1933.e2. https:\/\/doi.org\/10.1016\/j.jvir.2019.07.020.","journal-title":"J Vascul Int Radiol"},{"issue":"4","key":"3391_CR45","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s00261-018-1802-y","volume":"44","author":"T Kirchner","year":"2019","unstructured":"Kirchner T, Marquardt S, Werncke T, Kirstein MM, Brunkhorst T, Wacker F, et al. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Abdom Radiol. 2019;44(4):1554\u201361.","journal-title":"Abdom Radiol"},{"issue":"10","key":"3391_CR46","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","volume":"11","author":"R Salem","year":"2013","unstructured":"Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358\u201365.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"3391_CR47","doi-asserted-by":"publisher","first-page":"e045406","DOI":"10.1136\/bmjopen-2020-045406","volume":"11","author":"M Bakhit","year":"2021","unstructured":"Bakhit M, Jones M, Baker J, Nair R, Yan K, Del Mar C, et al. Reporting of adverse events, conflict of interest and funding in randomised controlled trials of antibiotics: a secondary analysis. BMJ Open. 2021;11(7):e045406.","journal-title":"BMJ Open"},{"issue":"5","key":"3391_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reaction: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"8","key":"3391_CR49","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jnci\/djab015","volume":"113","author":"ZW Veitch","year":"2021","unstructured":"Veitch ZW, Shepshelovich D, Gallagher C, Wang L, Abdul Razak AR, Spreafico A, et al. Underreporting of symptomatic adverse events in phase I clinical trials. J Natl Cancer Inst. 2021;113(8):980\u20138.","journal-title":"J Natl Cancer Inst"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03391-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03391-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03391-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T11:03:46Z","timestamp":1688555026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03391-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03391-4","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"31 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas Albrecht received speaker\u2019s honoraria from Sirtex Medical and Pharmacept, he consulted for Siemens Healthineers and operated as a proctor for Sirtex. Dirk Arnold received consulting fees and honoraria for presentations and lectures and travel support from Boston Scientific and Terumo, MSD, BMS, AstraZeneca, Roche, Servier, Sanofi and Merck Serono. He is on the guidelines committee of the European Society for Medical Oncology and supported oncopolicy manuscripts for the European Cancer Organisation. Irene Bargellini received: Institutional research grant from Boston Scientific; consulting fees from AstraZeneca, EISAI, Ge Healthcare, Guerbet, Merck, Sirtex, Terumo; honoraria for lectures from AstraZeneca, Bayer, Boston Scientific, Eisai, Guerbet, Merck, Sirtex, Sobi, Terumo; participation on Independent Data Safety Monitoring Board for AstraZeneca. Frank Kolligs participated on a data safety monitoring or advisory board of Bayer, MSD, and Roche. Geert Maleux received honoraria for speaker\u2019s bureau from Sirtex Medical and operated as a proctor for Sirtex Medical. Bruno Sangro received grants or contracts from Sirtex and BMS, consulting fees from Adaptimmune, Astra Zeneca, Bayer, BMS, Boston Scientific, Eisai, Eli Lilly, Incyte, Ipsen, Roche, Sirtex Medical, Terumo; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Roche, Sirtex Medical; Participation on a Data Safety Monitoring Board or Advisory Board from Adaptimmune, Astra Zeneca, Bayer, BMS, Boston Scientific, Eisai, Eli Lilly, Incyte, Ipsen, Roche, Sirtex Medical, Terumo, and has a leadership or fiduciary role in the International Liver Cancer Association. Jos\u00e9 I. Bilbao operated as proctor for Sirtex Medical. Niklaus Schaefer, Graham Munneke, Roberto Cianni, Bora Peynircioglu, Helena Pereira, Bleranda Zeka, Niels de Jong and Thomas Helmberger had nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All included patients signed an informed consent form. This research project was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}}]}}